VIDEO: PFS longer with combination of zanubrutinib plus obinutuzumab vs. obinutuzumab alone
Click Here to Manage Email Alerts
CHICAGO – In this Healio video exclusive, Christopher Flowers, MD, discusses how the combination of zanubrutinib and obinutuzumab vs. obinutuzumab alone leads to longer PFS in patients with relapsed/refractory follicular lymphoma.
When presenting at the American Society of Clinical Oncology Meeting, Flowers, professor and chair of the UT MD Anderson Department of lymphoma and myeloma, discussed the updated results to the ROSEWOOD clinical study.
“The updated study results showed an overall response rate that, looking across all predefined subgroups, favored zanubrutinib plus obinutuzumab vs. obinutuzumab alone,” Flowers said. “One of the things that’s interesting about the study is that when you look at infusion-related reactions that accord with the obinutuzumab, those were actually attenuated in the group that got zanubrutinib plus obinutuzumab with lower infusion-related reactions.”
ROSEWOOD is a phase 2, randomized study “designed at a 2:1 randomization where 145 patients were randomized to the zanubrutinib plus obinutuzumab arm and 72 patients were randomized to the obinutuzumab alone arm,” Flowers said.
Zanubrutinib plus obinutuzumab had a median PFS rate of 28 months vs. obinutuzumab alone having 10 months. Zanubrutinib plus obinutuzumab demonstrated meaningful activity and a manageable safety profile in patients with relapsed/refractory follicular lymphoma, representing a potential novel combination therapy.
“Overall, these efficacy results favored that the zanubrutinib plus obinutuzumab with a toxicity profile that was quite tolerable in both arms of the study.”
Collapse
Flowers, C, et al. Abstract 7545. Presented at: American Society of Clinical Oncology Meeting; June 2-6, 2023; Chicago.
Read more about
Click Here to Manage Email Alerts